AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20068567
Drug: weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: weekly docetaxel with cisplatin and 5-fluorouracil (wTCF)
Trial: 20068567
Drug: weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: weekly docetaxel with capecitabine (wTX)
Trial: 18608841
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of model demonstrations and practice (with and without knowledge of performance)
Trial: 18608841
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of model demonstrations and knowledge of performance practice
Trial: 16123681
Drug: stavudine or
RxNorm normalized name: stavudine Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: stavudine or nucleoside reverse transcriptase inhibitor regimens not containing didanosine
Trial: 6761122
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg alinidine
Trial: 6761122
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg alinidine
Trial: 6761122
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg alinidine
Trial: 29417135
Drug: Guselkumab, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab, 200 mg, by subcutaneous injection at weeks 0 and 4
Trial: 27051309
Drug: Low-dose SFC
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose SFC (100 µg, two puffs daily)
Trial: 27051309
Drug: High-dose fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fluticasone propionate (FP) alone (500 µg, daily)
Trial: 25280804
Drug: Outpatient interdisciplinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient interdisciplinary rehabilitation programme consisting of 6 weeks of intensive physiotherapy and individual occupational therapy as needed.
Trial: 9678811
Drug: Nizatidine 150
RxNorm normalized name: nizatidine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 150 mg b.d. with clarithromycin (500 mg) and amoxycillin (1000 mg) b.d. for 14 days
Trial: 9678811
Drug: Nizatidine 300
RxNorm normalized name: nizatidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 300 mg b.d. with clarithromycin (500 mg) and amoxycillin (1000 mg) b.d. for 14 days
Trial: 2454343
Drug: Antiarrhythmic drugs
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drugs (etmozin, quinidine, mexytil, allapinin, cordarone) used alone
Trial: 2454343
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of antiarrhythmic drugs
Trial: 31952554
Drug: Short-course therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course therapy (SCT) - 5-day intravenous antimicrobial therapy if clinical improvement is observed
Trial: 31952554
Drug: Conventional long-course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional long-course therapy (LCT) - at least 7 days of intravenous antibiotics
Trial: 22147778
Drug: Helium-oxygen therapy
RxNorm normalized name: helium / oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helium-oxygen therapy
Trial: 19567452
Drug: Acenocumarine 1
RxNorm normalized name: Acenocoumarin
DrugBank: Acenocoumarol (DB01418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acenocumarine 1 mg/day for 3 days before and 8 days after CVC insertion
Trial: 19567452
Drug: Dalteparin 5000
RxNorm normalized name: dalteparin 5000 intl units/0.2 mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin 5000 IU 2 h before and daily for 8 days after CVC insertion
Trial: 19567452
Drug: No anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anticoagulant treatment (NT)
Trial: 10512128
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion (CI) cisplatin 5 mg/m2/day plus etoposide 18 mg/m2/day for 5 days per week over 5 weeks with concurrent single daily fraction thoracic radiotherapy to 4500 cGy
Trial: 2202264
Drug: TUR +
RxNorm normalized name: Trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TUR + BCG (75 mg)
Trial: 2202264
Drug: BCG (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG (75 mg) for therapy of carcinoma in situ
Trial: 26809984
Drug: Pemetrexed plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G)
Trial: 17929018
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (L-AmB)
Trial: 17470822
Drug: Vitamin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin therapy (2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12)
Trial: 12472998
Drug: Braun Oral‐B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Braun Oral‐B 3D Excel power toothbrush (BPT)
Trial: 9797188
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg L-NMMA
Trial: 11004017
Drug: L-arginine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (30 g over 30 min)
Trial: 8634659
Drug: beta‐carotene (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta‐carotene (20 mg)
Trial: 8634659
Drug: DL-alpha-tocopheryl acetate
RxNorm normalized name: DL-alpha-tocopheryl acetate
DrugBank: DL-alpha tocopheryl acetate (DB14477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DL-alpha-tocopheryl acetate (55 mg)
Trial: 9161744
Drug: Lidocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 mg.kg‐1)
Trial: 378005
Drug: Intravenous cephalothin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cephalothin
Trial: 22298434
Drug: Pre-treatment patient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment patient variables including personality disorder pathology
Trial: 17087839
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl 2 microg kg(‐1)
Trial: 15041600
Drug: Dexamethasone 12
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 12 mg IV
Trial: 15041600
Drug: Droperidol 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 0.1 mg/mL with morphine in PCA
Trial: 11133606
Drug: Dexamethasone 4
RxNorm normalized name: dexamethasone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 4 mg IV
Trial: 15041600
Drug: Dexamethasone 2
RxNorm normalized name: dexamethasone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 2 mg IV
Trial: 8990448
Drug: Oral HRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral HRT (estradiol 2.0 mg/d + norethisterone acetate 1.0 mg/d)
Trial: 8990448
Drug: Transdermal HRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal HRT (estradiol 50 micrograms/d + medroxyprogesterone acetate 10 mg/d)
Trial: 8484508
Drug: Ketorolac, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac, 60 mg
Trial: 3437794
Drug: 20 X
RxNorm normalized name: betibeglogene autotemcel 2 x 10exp6 to 20 x 10exp6 cell/mL INTRAVEN PLASTIC BAG, INJECTION (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 X 10(6) IU/m2 of recombinant interferon (rIFN)‐alpha‐2A, I.M., twice a week for 6 months
Trial: 3437794
Drug: 10 X
RxNorm normalized name: PAD,ABDOMINAL 10 X 12 NONSTERILE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 X 10(6) IU/m2 of recombinant interferon (rIFN)‐alpha‐2A, I.M., twice a week for 6 months
Trial: 3437794
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of rIFN
Trial: 3437794
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of rIFN
Trial: 3437794
Drug: Long-term rIFN‐alpha‐2A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-term rIFN‐alpha‐2A therapy
Trial: 23524841
Drug: Aspirin (81,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81, 162.5, 325, 650, or 1300 mg daily for 12 weeks)
Trial: 19468757
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Risedronate and Estradiol
Trial: 9392404
Drug: UNICEF group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UNICEF group with restrictive fluid supplements and avoidance of bottles and pacifiers during the first 5 days of life
Trial: 8156252
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) 100 mg i.v. twice a day for 7 days followed by 400 mg orally three times a day
Trial: 3784916
Drug: Percutaneous 17
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous 17 beta-oestradiol 3 mg daily + 200 mg oral micronised progesterone
Trial: 3784916
Drug: Percutaneous 17
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous 17 beta-oestradiol 3 mg daily + 300 mg oral micronised progesterone
Trial: 3784916
Drug: Percutaneous 17
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous 17 beta-oestradiol 3 mg daily + 200 mg or 300 mg oral micronised progesterone
Trial: 15930042
Drug: TNF-alpha 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF-alpha 0.5 mg
Trial: 15930042
Drug: TNF-alpha 1
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF-alpha 1 mg
Trial: 15930042
Drug: TNF-alpha 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF-alpha 2 mg
Trial: 15930042
Drug: TNF-alpha 3/4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF-alpha 3/4 mg
Trial: 15930042
Drug: All TNF-alpha
RxNorm normalized name: all-rac-alpha-tocopherol
DrugBank: DL-alpha-Tocopherol (DB14476)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All TNF-alpha doses
Trial: 15930042
Drug: Higher TNF-alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher TNF-alpha doses
Trial: 12027069
Drug: Biminne capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biminne capsules (5 capsules twice a day for 12 weeks)
Trial: 12027069
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 capsules twice a day for 12 weeks)
Trial: 12027069
Drug: Biminne (dose-response
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biminne (dose-response study)
Trial: 12027069
Drug: Biminne treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biminne treatment
Trial: 9500317
Drug: Low-dose cyclosporin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclosporin (trough blood concentrations of 75-125 ng/mL)
Trial: 9500317
Drug: Normal-dose cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-dose cyclosporin (trough blood concentrations of 150-250 ng/mL)
Trial: 9500317
Drug: Normal-dose cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-dose cyclosporin
Trial: 21989185
Drug: 4 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cycles of anthracycline chemotherapy
Trial: 17287823
Drug: NBI‐34041 (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBI‐34041 (10, 50, or 100 mg)
Trial: 7944433
Drug: Portal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Portal infusion chemotherapy (n=5)
Trial: 7944433
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy (n=6)
Trial: 7944433
Drug: Arterial infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arterial infusion chemotherapy (n=8)
Trial: 3984837
Drug: Cibenzoline (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibenzoline (1.0 mg/kg IV, then 1 mg/kg increments to a maximum of 3.0 mg/kg)
Trial: 3984837
Drug: Procainamide (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procainamide (1000 mg IV, then 1500 mg)
Trial: 3984837
Drug: Chronic oral
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic oral cibenzoline therapy (mean follow-up of 8.8 months)
Trial: 15037402
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (80 mg daily)
Trial: 30477827
Drug: 700 mg
RxNorm normalized name: cystine 700 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 700 mg Zataria multiflora Boiss. (Shirazi thyme) powder twice daily for 12 weeks
Trial: 27538497
Drug: DA9301 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA9301 (1000 mg/day for 4 weeks)
Trial: 25306810
Drug: Conventional circumcision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional circumcision (CC), n = 120
Trial: 19819914
Drug: 3-weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-weekly docetaxel (group D)
Trial: 19819914
Drug: 3-weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-weekly docetaxel alternating with 3-weekly gemcitabine (group D/G)
Trial: 15077032
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide inhalation (20 ppm administered 10 min after reperfusion)
Trial: 15077032
Drug: Placebo gas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gas (administered 10 min after reperfusion)
Trial: 10680840
Drug: VEGF plasmid/liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEGF plasmid/liposome (P/L) gene transfer (1000 microg of VEGF)
Trial: 10680840
Drug: beta-galactosidase plasmid/liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-galactosidase plasmid/liposome (P/L) gene transfer (1000 microg of beta-galactosidase)
Trial: 8245283
Drug: Pill placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill placebo plus clinical management
Trial: 30415650
Drug: Eperisone hydrochloride
RxNorm normalized name: Eperisone hydrochloride
DrugBank: Eperisone (DB08992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eperisone hydrochloride 50 mg (sugar-coated tablet)
Trial: 30415650
Drug: Eperisone hydrochloride
RxNorm normalized name: Eperisone hydrochloride
DrugBank: Eperisone (DB08992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eperisone hydrochloride 50 mg (film-coated tablet)
Trial: 30415650
Drug: Eperisone hydrochloride
RxNorm normalized name: Eperisone hydrochloride
DrugBank: Eperisone (DB08992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eperisone hydrochloride 50 mg (both formulations)
Trial: 19247757
Drug: Intranasal 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal 5% lidocaine plus naphazoline solution 0.2 mg ml(‐1)
Trial: 19247757
Drug: Topical intranasal
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical intranasal saline 20 ml (control group)
Trial: 10768245
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g i.v. 30 min preinterventionally
Trial: 10768245
Drug: No study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No study medication (control group)
Trial: 9357093
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (500 mg sodium valproate) under fasting conditions (treatment A)
Trial: 9357093
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (500 mg sodium valproate) after ingestion of 14 g citrus pectin (treatment B)
Trial: 3081599
Drug: Cromolyn (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cromolyn (12 doses of 20 mg)
Trial: 3081599
Drug: Cromolyn (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cromolyn (single dose)
Trial: 20496791
Drug: Sporobakterin liquid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sporobakterin liquid, a suspension for oral use
Trial: 16098081
Drug: Peginterferon alpha-2a
RxNorm normalized name: PEGINTERFERON ALPHA-2A 180MCG/ML INJ,1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon alpha-2a 180 mg/week with ribavirin for 48 weeks
Trial: 16098081
Drug: Peginterferon alpha-2a
RxNorm normalized name: PEGINTERFERON ALPHA-2A 180MCG/ML INJ,1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon alpha-2a 180 mg/week without ribavirin for 48 weeks
Trial: 16098081
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (peginterferon/ribavirin)
Trial: 10099040
Drug: Ceftibuten alone
RxNorm normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftibuten alone (400 mg)
Trial: 10099040
Drug: Ceftibuten with
RxNorm normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftibuten with antacid (Mylanta Double-Strength Liquid; 60 mL)
Trial: 10099040
Drug: Ceftibuten with
RxNorm normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftibuten with ranitidine (150 mg/12 hours after 3 days of dosing)
Trial: 20924607
Drug: IVIG 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 0.5 g/kg at 12 h postnatal age
Trial: 20924607
Drug: IVIG 1
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 1 g/kg at 12 h postnatal age
Trial: 20924607
Drug: IVIG group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG group (both doses)
Trial: 19170847
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone patch (TTP)
Trial: 16689842
Drug: No beta-blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No beta-blocker therapy (MI patients)
Trial: 11251672
Drug: Intensive education
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive education on lifestyle (diet, exercise, smoking) with polypharmacological treatment
Trial: 9924378
Drug: Control (anti-inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (anti-inflammatory drugs only)
Trial: 7816294
Drug: Emla cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emla cream applied for at least 2 hours prior to injection
Trial: 3140155
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium 4% ophthalmic solution (Opticrom)
Trial: 3140155
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching drug vehicle)
Trial: 30540619
Drug: Task-oriented EMG-triggered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Task-oriented EMG-triggered electrical stimulation therapy for wrist/finger extensors in addition to conventional physical therapy for 5 sessions a week for 4 weeks.
Trial: 30540619
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy for 20 sessions.
Trial: 30540619
Drug: Task-oriented EMG-triggered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Task-oriented EMG-triggered electrical stimulation therapy.
Trial: 27131100
Drug: Electrolyte maintenance
RxNorm normalized name: Truelyte Advanced Hydration Electrolyte Maintenance Solution (Fruit Punch)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrolyte maintenance solution (n=324)
Trial: 24456217
Drug: rosuvastatin 5
RxNorm normalized name: rosuvastatin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 5 mg/day or 10 mg/day
Trial: 16192591
Drug: Doxorubicin 50
RxNorm normalized name: DOXOrubicin 50 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 50 mg/m² and Docetaxel 75 mg/m² (AT)
Trial: 16192591
Drug: Fluorouracil 500
RxNorm normalized name: fluorouracil 500 MG in 10 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil 500 mg/m², Doxorubicin 50 mg/m², and Cyclophosphamide 500 mg/m² (FAC)
Trial: 12047485
Drug: Dextromethorphan (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (0.7 mg kg(‐1))